Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845413 | 0.86 | PDE1B (0.49) | DPP4HTR2CHTR2AHTR2BCLPP | |
| Acetic Acid SCHEMBL22717314 | 0.84 | PDE1B (0.46) | DPP4HTR2CHTR2AHDAC1HDAC6 | |
| SCHEMBL22717381 | 0.80 | GNRHR (0.37) | DPP4HTR2CHTR2AHTR2B | |
| SCHEMBL22845436 | 0.76 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL24914845 | 0.73 | CLPP (0.64) | CLPP | |
| SCHEMBL22845477 | 0.71 | P2RX3 (0.46) | DPP4HDAC1HDAC6 | |
| SCHEMBL24914438 | 0.70 | CLPP (0.66) | CLPP | |
| SCHEMBL24915173 | 0.70 | CLPP (0.61) | CLPP | |
| SCHEMBL24914722 | 0.70 | CLPP (0.67) | CLPP | |
| SCHEMBL24915185 | 0.70 | CLPP (0.54) | CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | DPP4 361/4885HTR2C 467/4885HTR2A 1702/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | DPP4 361/4885HTR2C 467/4885HTR2A 1702/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | DPP4 361/4885HTR2C 467/4885HTR2A 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.